Publication: Dabigatran versus warfarin: Effects on ischemic and hemorrhagic strokes and bleeding in asians and non-Asians with atrial fibrillation
dc.contributor.author | Masatsugu Hori | en_US |
dc.contributor.author | Stuart J. Connolly | en_US |
dc.contributor.author | Jun Zhu | en_US |
dc.contributor.author | Li Sheng Liu | en_US |
dc.contributor.author | Chu Pak Lau | en_US |
dc.contributor.author | Prem Pais | en_US |
dc.contributor.author | Denis Xavier | en_US |
dc.contributor.author | Sung Soon Kim | en_US |
dc.contributor.author | Razali Omar | en_US |
dc.contributor.author | Antonio L. Dans | en_US |
dc.contributor.author | Ru San Tan | en_US |
dc.contributor.author | Jyh Hong Chen | en_US |
dc.contributor.author | Supachai Tanomsup | en_US |
dc.contributor.author | Mitsunori Watanabe | en_US |
dc.contributor.author | Masahide Koyanagi | en_US |
dc.contributor.author | Michael D. Ezekowitz | en_US |
dc.contributor.author | Paul A. Reilly | en_US |
dc.contributor.author | Lars Wallentin | en_US |
dc.contributor.author | Salim Yusuf | en_US |
dc.contributor.other | Osaka Medical Center for Cancer and Cardiovascular Diseases | en_US |
dc.contributor.other | Population Health Research Institute, Ontario | en_US |
dc.contributor.other | Fuwai Hospital | en_US |
dc.contributor.other | The University of Hong Kong | en_US |
dc.contributor.other | Research Institute | en_US |
dc.contributor.other | Yonsei University College of Medicine | en_US |
dc.contributor.other | Institut Jantung Negara Kuala Lumpur | en_US |
dc.contributor.other | Philippine General Hospital | en_US |
dc.contributor.other | National Heart Centre, Singapore | en_US |
dc.contributor.other | National Cheng Kung University Hospital | en_US |
dc.contributor.other | Mahidol University | en_US |
dc.contributor.other | Nippon Boehringer Ingelheim Co., Ltd. | en_US |
dc.contributor.other | Jefferson Medical College | en_US |
dc.contributor.other | Boehringer Ingelheim Pharmaceuticals, Inc. | en_US |
dc.contributor.other | Akademiska Sjukhuset | en_US |
dc.date.accessioned | 2018-10-19T05:22:19Z | |
dc.date.available | 2018-10-19T05:22:19Z | |
dc.date.issued | 2013-07-01 | en_US |
dc.description.abstract | BACKGROUND AND PURPOSE - : Intracranial hemorrhage rates are higher in Asians than non-Asians, especially in patients receiving warfarin. This randomized evaluation of long-term anticoagulation therapy subgroup analysis assessed dabigatran etexilate (DE) and warfarin effects on stroke and bleeding rates in patients from Asian and non-Asian countries. METHODS - : There were 2782 patients (15%) from 10 Asian countries and 15 331 patients from 34 non-Asian countries. A Cox regression model, with terms for treatment, region, and their interaction was used. RESULTS - : Rates of stroke or systemic embolism in Asians were 3.06% per year on warfarin, 2.50% per year on DE 110 mg BID (DE 110), and 1.39% per year on DE 150 mg BID (DE 150); in non-Asians, the rates were 1.48%, 1.37%, and 1.06% per year with no significant treatment-by-region interactions. Hemorrhagic stroke on warfarin occurred more often in Asians than non-Asians (hazard ratio [HR], 2.4; 95% confidence interval [CI], 1.3-4.7; P=0.007), with significant reductions for DE compared with warfarin in both Asian (DE 110 versus warfarin HR, 0.15; 95% CI, 0.03-0.66 and DE 150 versus warfarin HR, 0.22; 95% CI, 0.06-0.77) and non-Asian (DE 110 versus warfarin HR, 0.37; 95% CI, 0.19-0.72 and DE 150 versus warfarin HR, 0.28; 95% CI, 0.13-0.58) patients. Major bleeding rates in Asians were significantly lower on DE (both doses) than warfarin (warfarin 3.82% per year, DE 110 2.22% per year, and DE 150 2.17% per year). CONCLUSIONS - : Hemorrhagic stroke rates were higher on warfarin in Asians versus non-Asians, despite similar blood pressure, younger age, and lower international normalized ratio values. Hemorrhagic strokes were significantly reduced by DE in both Asians and non-Asians. DE benefits were consistent across Asian and non-Asian subgroups. CLINICAL TRIAL REGISTRATION - : URL: http://www.clinicaltrials.gov. Unique identifier: NCT00262600. © 2013 American Heart Association, Inc. | en_US |
dc.identifier.citation | Stroke. Vol.44, No.7 (2013), 1891-1896 | en_US |
dc.identifier.doi | 10.1161/STROKEAHA.113.000990 | en_US |
dc.identifier.issn | 15244628 | en_US |
dc.identifier.issn | 00392499 | en_US |
dc.identifier.other | 2-s2.0-84879962384 | en_US |
dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/20.500.14594/32284 | |
dc.rights | Mahidol University | en_US |
dc.rights.holder | SCOPUS | en_US |
dc.source.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84879962384&origin=inward | en_US |
dc.subject | Medicine | en_US |
dc.subject | Nursing | en_US |
dc.title | Dabigatran versus warfarin: Effects on ischemic and hemorrhagic strokes and bleeding in asians and non-Asians with atrial fibrillation | en_US |
dc.type | Article | en_US |
dspace.entity.type | Publication | |
mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84879962384&origin=inward | en_US |